^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
EMPLICITI is a SLAMF7-directed immunostimulatory antibody indicated in...combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Secondary therapy:
dexamethasone
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
The NCCN panel has included the combination of pomalidomide/dexamethasone/elotuzumab as an option for patients who have received at least two prior therapies...
Secondary therapy:
dexamethasone